Your browser doesn't support javascript.
loading
Large-scale real-world data analysis of source plasma collections using a novel technology-enabled nomogram.
Hellman, Eva; Manukyan, Zorayr; Mkhitaryan, Karen; Heidarsdottir, Karen; Ragusa, Michael J; Hartmann, Jan.
Afiliación
  • Hellman E; Global Medical Office, Haemonetics Corporation, Boston, Massachusetts, USA.
  • Manukyan Z; ClinStatDevice, Lexington, Massachusetts, USA.
  • Mkhitaryan K; ClinStatDevice, Lexington, Massachusetts, USA.
  • Heidarsdottir K; Quality and Postmarket Surveillance, Haemonetics Corporation, Boston, Massachusetts, USA.
  • Ragusa MJ; Research and Development, Haemonetics Corporation, Boston, Massachusetts, USA.
  • Hartmann J; Global Medical Office, Haemonetics Corporation, Boston, Massachusetts, USA.
Transfusion ; 63(12): 2256-2264, 2023 12.
Article en En | MEDLINE | ID: mdl-37839089
BACKGROUND: Source plasma collections are needed to satisfy the growing demand for plasma-derived medicinal products. The US plasma collection target volume has been guided by a standard weight-based FDA-issued nomogram (STAN) since 1992. In this research, large-scale US-based real-world data (RWD) were analyzed to confirm the safety and volume gains of a newly introduced personalized nomogram (PERS) that was previously studied in a premarket randomized controlled environment. STUDY DESIGN AND METHODS: A non-inferiority (NI) analysis was conducted to compare the novel nomogram's significant hypotensive adverse event (AE) incidence rate with large historical standard nomogram AE datasets. Additionally, the average target volumes and donor return rates were compared for collections following PERS and STAN. RESULTS: A total of 4,816,784 donations (PERS) by 414,957 donors resulted in a rate of 0.0998% (95% CI [0.0970, 0.1027]) significant hypotensive AEs. NI analysis suggested strong non-inferiority of the new technology (Δ = -0.0082%, 95% CI [-0.0113, -0.0050], prespecified NI margin = 0.1080). Average plasma collection target volumes increased by 66.39 mL (8.49%; p < .0001). Consecutive weekly donor return rates were consistent between the two nomograms (PERS: 73.6%, 95% CI [69.6%-76.7%]; STAN: 74.1%, 95% CI [66.1%-77.2%]). DISCUSSION: This analysis confirms in a large-scale real-world dataset the key safety parameter and collection benefit of a novel, technology-enabled nomogram. The nomogram may help meet the growing demand for plasma-derived therapies by providing approximately 8.5% more plasma per donation on average while maintaining donor safety and return rates.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nomogramas / Hipotensión Límite: Humans Idioma: En Revista: Transfusion Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nomogramas / Hipotensión Límite: Humans Idioma: En Revista: Transfusion Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos